Patients with glioblastoma currently do not sufficiently benefit from recent breakthroughs in
cancer treatment that use checkpoint inhibitors 1 , 2 . For treatments using checkpoint …

Meningiomas are the most common intracranial tumors. Yet, only few controlled clinical
trials have been conducted to guide clinical decision making, resulting in variations of …

Background There is an urgent need for more effective therapies for glioblastoma. Data
from a previous unrandomised phase 2 trial suggested that lomustine-temozolomide plus …

Background Radiotherapy is the standard care in elderly patients with malignant astrocytoma
and the role of primary chemotherapy is poorly defined. We did a randomised trial to …

The factors driving therapy resistance in diffuse glioma remain poorly understood. To
identify treatment-associated cellular and genetic changes, we analyzed RNA and/or DNA …

Meningiomas are the most common primary intracranial tumour in adults 1 . Patients with
symptoms are generally treated with surgery as there are no effective medical therapies. The …

Mutated isocitrate dehydrogenase 1 (IDH1) defines a molecularly distinct subtype of diffuse
glioma 1 , 2 – 3 . The most common IDH1 mutation in gliomas affects codon 132 and …

Background Addition of temozolomide (TMZ) to radiotherapy (RT) improves overall survival (OS)
in patients with glioblastoma (GBM), but previous studies suggest that patients with …

Major depression is a highly prevalent severe mood disorder that is treated with antidepressants.
The molecular targets of antidepressants require definition. We investigated the role of …

The evolutionary processes that drive universal therapeutic resistance in adult patients with
diffuse glioma remain unclear 1 , 2 . Here we analysed temporally separated DNA-…